In Vitro Biotransformation in Drug Discovery by Ravindran, Selvan et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 1
In Vitro Biotransformation in Drug Discovery
Selvan Ravindran, Rutuja Rokade, Jitendra K. Suthar,
Pooja Singh, Pooja Deshpande,
Rajeshree Khambadkar and Srushti Utekar
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/intechopen.73173
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited. 
Selvan Ravindran, Rutuja Rokade, Jitendra K. Suthar, 
Pooja Singh, Pooja Deshpande, Rajeshree Khambadkar
and Srushti Utekar
Additional information is available at the end of the chapter
Abstract
In vitro Biotransformation studies play a crucial role in drug discovery program that 
determine the fate of the new chemical entities (NCE’s). Enzyme rich matrices such as 
microsomes, hepatocytes, liver fractions and S9 fractions transform the new chemical 
entities to different metabolites. Metabolites could be pharmacologically important or 
toxic. Newly formed metabolites are identified using liquid chromatography interfaced 
with mass spectrometry. Identification of the biotransformation sites in the new chemical 
entity helps the medicinal chemists to optimize its structure and develop the NCE as a 
pharmaceutical drug. Screening pharmaceutical drugs using in vitro biotransformation 
studies assist in selecting the right new chemical entity for further in vivo studies in ani-
mal systems and later in human clinical trials.
Keywords: In vitro biotransformation, metabolism, drug discovery, chromatography, 
mass spectrometry
1. Introduction
Organisms such as Enzymes, Bacteria and Fungi play a crucial role in the conversion of organic 
compounds to different products. This process of transformation is termed as biotransforma-
tion. In different fields of science, biotransformation has a significant impact. In the case of drug 
discovery and development, metabolism of drug to many different compounds is catalyzed by 
the enzymes in the liver [1, 2]. Similarly microorganisms in the gut are responsible for microbial 
biotransformation of organic compounds [3]. Most of the pharmaceutical drugs are organic 
moieties and undergo enzymatic biotransformation or microbial biotransformation. Therefore, 
in vitro biotransformation studies that mimics the actual in vivo system gains importance.
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the t rms of the Crea ive
Comm ns Attribution Lic nse (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
In vivo studies on various species are not economical and have restrictions; therefore In vitro 
biotransformation studies are vital in drug discovery programs [4]. Screening pharmaceuti-
cally important compounds using in vitro matrices such as microsomes, hepatocytes, liver 
slices and S9 fractions from different species directs the drug discovery team to make an 
appropriate decision to advance the molecules. Incubation of new chemical entities as well 
as pharmaceutical compounds with different in vitro matrices [5–8] results in metabolites. 
Metabolites could be pharmacologically important or it could be toxic [9].
Metabolites are identified and characterized using liquid chromatography and mass spec-
trometry (LC–MS/MS) [10]. In vitro biotransformation studies performed on various species 
guides the researchers to choose the right animal model to validate the developed molecule 
[11, 12]. Thus the in vitro biotransformation studies assist to identify and eliminate the false 
positives and make it possible to choose the relevant molecule for further In Vivo studies 
and later for clinical trials. Biotransformation of pharmaceutical drugs with different struc-
tural moieties results in different metabolite structures. Liquid chromatography assists in 
separation of the metabolites and drugs according to the polarity of the molecules. Liquid 
chromatography also provides a vital information to purify the drugs, metabolites and nano 
materials that serves as delivery systems for various biomedical applications [13, 14]. Mass 
Spectrometry resort to identify the mass of the drugs, metabolites and thus helpful to assign 
the biotransformation sites in the metabolites [10, 12].
2. In vitro metabolism of drugs by Microsomes
The important site of the body for drug metabolism is liver. Membrane bound drug metabo-
lizing enzymes were present in liver microsomes as subcellular fractions. Hepatic CYP-450 
enzymes were the reason for metabolism and clearance of more than 60% of marketed com-
pounds [5, 15]. In Vito intrinsic clearance of a compound is determined using microsomes and 
interspecies differences in drug metabolism using species-specific microsomes. Commercially 
available microsomes for rat, mouse, dog and cyanomolgus monkey were used to understand 
the interspecies differences [11, 12].
Microsomal stability assays performed for a drug is used to calculate in vitro half-life (T1/2) for a particular drug and also intrinsic clearance (CLint). Thus microsomes are ideal model systems 
to determine the metabolic stability, phase-I metabolism and intrinsic clearance of a compound 
that can be scaled to in vivo situation to predict human clearance [5]. Control compounds such 
as Verapamil, Diazepam, Diphenylhydramine, Quinidine and Dextromethorphan are used 
as matrices for human, rat, mouse, monkey and dog respectively to compare the deviation 
of test compounds. Both the control and test incubations were performed in the absence of 
NADPH (Nicotinamide Adenine Dinucleotide Phosphate) to identify the chemical stability of 
compounds or non enzyme mediated pathway and in the presence of NADPH to determine 
the enzyme mediated metabolism.
Microsomes were prepared, stored and used conveniently in comparison to whole cell mod-
els. Microsomes are generally used to screen hundreds of compounds in drug discovery 
and development and rank order the compounds. Compounds are rank ordered as high, 
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medium and low clearance compounds. For example intrinsic clearance value of >47 μL/
min/mg protein for a particular drug in human liver microsomes is considered to be high 
and intrinsic clearance value of <8.6 μL/min/mg protein is considered as low clearance. 
Intrinsic clearance value between 47 μL/min/mg protein and 8.6 μL/min/mg protein is con-
sidered to be moderate intrinsic clearance. Similarly for monkey, dog, rat and mouse high, 
medium and low clearance values were assigned based on the extensive studies done for 
many compounds [15, 16].
Predominantly microsomal stability studies are performed to assure the Phase-I metabolism 
in the presence of NADPH as cofactor (Figure 1). Besides this microsomes can also be utilized 
to understand the Phase-II metabolic pathway of a compound. Incubating the test compound 
in the presence of microsomes, NADPH and UDPGA (Uridine Diphosphate Glucoronic Acid) 
would reveal the possible glucoronide pathway. Similarly incubation of a parent drug with 
NADPH and Glutathione helps to identify the conjugation site for glutathione and its pathway.
3. In vitro metabolism of drugs by hepatocytes
Intact cell of hepatocytes consists of both Phase-I and Phase-II drug metabolizing enzymes. 
Hence, hepatocytes based studies to identify the intrinsic clearance of compound mimics In 
Vivo system to a greater extent than microsomes [16]. While, microsomes are rich in Phase-I 
enzymes, hepatocytes consists of both Phase-I and Phase-II enzymes. Quantity of Phase-I 
enzymes were abundant in microsomes and helps to detect the Phase-I metabolites with 
accuracy, but lacks Phase-II enzymes. Hepatocytes derived from various species such as 
rat, mouse, dog, monkey and human were imperative to understand the impact of species 
Figure 1. In vitro biotransformation scheme to screen pharmaceutical drugs.
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differences in metabolism. Hepatocytes studies help to identify the species akin to that of 
humans and choose the model system for further studies of any drug [17]. Thus Human 
hepatocytes serve as a gold standard to understand the metabolism and toxicity of drugs.
Hepatocytes are cryopreserved and stored for longer duration of time. Cell viability and activity 
are better with cryopreserved hepatocytes and best alternatives for fresh cells. Presence of both 
phase-I and phase-II enzymes result in better assessment for clearance of drugs [18, 19]. Based 
on intrinsic clearance values compounds can be rank ordered as low, medium and high using 
hepatocytes for different species. Intrinsic clearance for humans range from <3.5 to >19.0 μL/
min/106 cells, in the case of monkey <5.2 and >28.3 μL/min/106 cells; for dog <1.9 and >10.5 μL/
min/106 cells; for rat <5.1 and >27.5 μL/min/106 cells and mouse <3.3 and 17.8 μL/min/106 cells.
4. Microsomes versus hepatocytes
Compounds that are metabolized by phase-II enzymes are best studied by hepataocytes, com-
pounds whose primary metabolic pathway is through phase-I enzymes is best understood by 
microsomes (Figure 2). Microsomes are rich in CYP450 enzymes and therefore metabolic turn-
over is very high compared to that of hepatocytes. Compounds with the property of poor perme-
ability through cell membranes are more stable in hepatocytes than microsomes. Identification 
of phase-I metabolites using microsomes are confirmatory while phase-II metabolite identifica-
tion can be authenticated using hepatocytes. Quantities of enzymes are less in hepatocytes com-
pared to microsomes resulting in less quantity of metabolites for hepatocytes. Hence, in order 
to confirm few of the phase-II metabolites such as glucuronidation and glutathione conjuga-
tion, pharmaceutical drugs are incubated with microsomes along with cofactors such as UDPGA 
or Glutathione. Incubation of microsomes with drugs and cofactors result in more quantity of 
metabolites and can be quantified accurately.
Figure 2. Comparison of outcome of microsomes and hepatocytes upon incubation with pharmaceutical drugs.
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Thus both microsomes and hepatocytes are very much essential as a matrix to study the 
xenobiotics of pharmaceutical drugs. Prediction of clearance using hepatocytes is better and 
results are similar to that of in vivo systems [20, 21].
5. In vitro metabolism of drugs by liver slices
Metabolism plays a key role in detoxification of xenobiotics. Metabolic enzymes as well as 
transporter proteins that transfer the metabolites and parent drugs through the cells are essen-
tial for in vitro metabolism to mimic the in vivo metabolic systems [7]. Liver slices from human 
and various species are precious and valuable to conduct drug metabolism studies and acute 
toxicity studies [22, 23]. Metabolic enzyme activity of liver slices declines rapidly and restricts 
its prolonged use for drug metabolism studies. In spite of this inherent problem of liver slices 
pharmacological and toxicological studies have been performed and liver slices were proved 
to be one of the efficient model systems [23]. Precision cut liver slices consists of all liver cell 
types that are present in natural cells with cell to matrix and cell to cell interactions, thus 
representing actual liver functions [24]. Thus precision cut liver slices helps to recognize and 
identify the mechanisms for exposure in humans. Most of the precision cut liver slices with 
active enzyme components and cells are viable for not more than 2 days [25, 26]. Therefore 
modifications of culture conditions such as medium composition were attempted in recent 
years [27] to extend the viability of precision cut liver slices to 5 days with promising results.
6. In vitro metabolism of drugs by liver S9 fractions
Liver S9 fractions are rich in both microsomal and cytosolic fractions. Optimum metabolic 
information about a compound is obtained from liver S9 fractions than microsomes. Liver 
S9 fractions consist of both microsomal and cytosolic fractions and corresponding enzymes, 
whereas microsomes have only microsomal proteins. Isolation of liver S9 fractions is uncom-
plicated and obtained during the initial stages of microsomal preparations [28, 29]. Major 
components of cytosolic S9 fractions are cytochrome P450’s, Uridine 5′-diphospho-glucuro-
nosyltransferase, aldehyde oxidase, xanthine oxidase, sulfotransferases, methyl transferases, 
N-acetyl transferases, glutathione transferases and represents the in vivo system to a greater 
extend. Microsomes consists of CYP 450’s and Uridine 5′-diphospho-glucuronosyltrans-
ferase and lack other enzymes that are present in S9 fractions [30]. Similar to microsomes 
liver S9 fractions need cofactors such as β-Nicotinamide adenine dinucleotide phosphate- 
regenerating system (for oxidation), Uridine 5′-diphospho-α-D-glucuronic acid (glucuroni-
dation), 3′-phosphoadenosine-5′-phosphosulphate (Sulfate conjugation) and glutathione 
(glutathione conjugation) for phase-I and phase-II assays. Hepatocytes do not require any 
of these cofactors that are used during microsomal or liver S9 fractions based assays [31]. 
Human hepatocytes are considered to be golden standard and 7-ethoxy coumarin has been 
used as an appropriate substrate to understand the phase-I and phase-II metabolism [31] 
in different matrices. Recently liver S9 fractions were shown as a matrix comparable to that 
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of hepatocytes to screen compounds for metabolic stability assays [32]. Researchers have 
used 7-ethoxy coumarin and performed a comparative study on three different matrices i.e. 
microsomes, hepatocytes and liver S9 fractions. Phase-I metabolite 7-hyroxy coumarin was 
observed in all the three matrices, whereas glucuronide and sulfate conjugates were observed 
for hepatocyte and liver S9 fractions [33]. Therefore activities of liver S9 fractions are more 
akin to hepatocytes than that of microsomes.
7. Purified CYP enzymes for reaction phenotyping
Compounds that exhibit medium or high clearance in microsomes and hepatocytes assays are 
subjected to reaction phenotyping studies.
Expressed enzymes or purified CYP enzymes are used to identify the enzyme responsible 
for the metabolism of a particular compound and is termed as reaction phenotyping [34]. 
CYP enzymes CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 are primarily 
responsible for phase-I metabolism of most of the drugs. If phase-II metabolite glucuronide 
conjugate is expected, enzymes UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A9, UGT2B7 
and UGT2B15 need to screened. Thus the above mentioned purified enzymes need to be incu-
bated with a particular drug to identify the percentage contribution of each enzyme for the 
metabolism of a drug. During the reaction phenotyping assay positive controls are tested for 
each purified enzyme. Ethoxycoumarin is a positive control for CYP1A2; Amodiaquine for 
CYP2C8; Diclofenac for CYP2C9; Diazepam for CYP2C19, Dextromethorphan for CYP2D6; 
Testosterone for CYP3A4 and Efavirenz for CYP2B6. There are instances where a particu-
lar drug can result in different metabolites. Formation of each metabolite can be from same 
enzyme or due to different enzymes or due to the contribution of mixture of enzymes. Hence 
reaction phenotyping is essential to identify and confirm the enzyme responsible for the for-
mation of particular metabolite [35]. Knowledge from reaction phenotyping helps to suppress 
or enhance the formation of a particular metabolite using inhibitors or enhancers. In case a 
particular metabolite is expected to be toxic in expected quantity, then the formation of that 
metabolite can be suppressed using inhibitors. Reaction phenotyping studies will also help the 
medicinal chemist to design a synthetic strategy to avoid the formation of a toxic metabolite.
Thus the information derived from reaction phenotyping studies can be utilized to (1) predict 
drug–drug interactions with the coadministered drugs and (2) metabolism of a drug by an iso-
form can lead to increase or decrease in the concentration of drugs, metabolites in plasma and 
therefore difficult to determine the therapeutic range of a compound (3) helps medicinal chem-
ist to modify the structure of drug or pharmacologist to use an inhibitor or enhancer to address 
the safety of the drug (4) Generally compounds which exhibit high or medium clearance in the 
microsomal or hepatocyte stability assays are subjected to reaction phenotyping assays.
Food and Drug Administration also highly recommends in vitro studies to understand the 
systemic clearance and also to determine the responsible CYP450 or UDPGA enzyme for the 
metabolism of new investigational drug.
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8. CYP450 time dependent inhibition assay
Drug-drug interactions is caused by the inhibition of CYP450 enzymes. Inhibition is of three 
types (1) irreversible (2) Quasi reversible and (3) reversible. Irreversible CYP450 inhibition 
reactions are of major concern compared to that of reversible CYP450 inhibition, because syn-
thesis of inactivated enzyme is essential to restore the activity of deactivated enzymes. Hence 
it is mandatory to understand the mechanism of new chemical entities at an early stage of 
the drug discovery and development [36]. Two types of time dependent inhibition are gen-
erally referred as mechanism based inhibition (MBI) and time dependent inhibition (TDI). 
Mechanism based inhibition is due to the inhibition of enzyme by chemically derived metabo-
lite. Mechanism based inhibition is classified as a subset of time dependent inhibition. Time 
dependent inhibition arises when there is an increased inhibition during the incubation of 
test compound with metabolizing system prior to the addition of the substrate. Available CYP 
isoforms such as CYP3A4, CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19 and CYP2D6 are 
generally tested for CYP inhibition. The substrate used for CYP3A4 inhibition is midazolam 
and control compound is mifepristone; substrate for CYP1A2 is ethoxyresorufin and posi-
tive control compound is furafylline; substrate for CYP2B6 is bupropion and positive control 
compound is ticlopidine; substrate for CYP2C8 is paclitaxel and control compound is gemfi-
brozil; substrate for CYP2C9 is diclofenac and control compounds is tienilic acid; substrate for 
CYP2C19 is S-mephenytoin and control compound is ticlopidine and substrate for CYP2D6 
is dextromethorphan and control compound is paraxetine. These control compounds are 
inhibitors which are selected by screening few time dependent inhibitors. For example probe 
substrate of CYP3A4 midazolam can be subjected to inhibition studies using time dependent 
inhibitors like clarithromycin, verapamil, troglitazone, mfepristone and mibefradil. The inhib-
itor that exhibits maximum inhibition is chosen as the inhibitor for a CYP isoform. During the 
CYP inhibition experiments quantity of substrate, inhibitor and formation of metabolites is 
analyzed using liquid chromatography interfaced with mass spectrometry [37].
9. LC-MS/MS and In vitro biotransformation studies
Accurate bioanalytical methods are essential in drug discovery to assess the concentrations of 
drugs and metabolites. Pharmacokinetic investigations, toxicokinetic analysis and several in 
vitro studies such as metabolite identification, metabolic stability, caco-2 permeability stud-
ies, drug–drug interactions and protein binding studies are extensively studied using liquid 
chromatography hyphenated with mass spectrometry. Therefore, high throughput screening 
to develop methods is challenging and time dependent.
Chromatography and Mass Spectrometry plays a major role in determining the concentrations 
of drugs and metabolites at the levels of attomole or femtomole [38]. The science of separation 
achieved through chromatography is very important to separate the drugs and metabolites 
based on the polarity of the molecules. Advent of high performance liquid chromatography 
(HPLC) and ultra performance liquid chromatography (UPLC) resulted in analyzing samples 
In Vitro Biotransformation in Drug Discovery
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in shorter period of chromatography run time (1–5 min). Sensitive mass spectrometers such 
as triple quadrupole mass spectrometers, quadrupole ion trap mass spectrometers, orbi trap 
mass spectrometers, time-of-flight mass spectrometers have accelerated the detection of drugs 
and metabolites at very low quantity such as attomole levels and to identify the structure 
of drugs and metabolites. Thus chromatography hyphenated with mass spectrometers were 
supportive to address the LADMET (liberation, absorption, distribution, metabolism, excre-
tion and toxicity) related issues in drug discovery programs [39]. Quantitation by chromatog-
raphy and mass spectrometry is important to assess the liberation, absorption, distribution, 
excretion and toxicity of a drug molecule and its metabolites.
10. Quantitation of drugs and metabolites
Efficient sample preparation methods are essential for effective quantitative analysis of drugs 
and metabolites. Recovery of drugs and metabolites in high amount is an important factor in 
this process. Several methods such as liquid–liquid extraction, solid–liquid extraction, use of 
sep-pak cartridges, elution of drugs and metabolites through small columns packed with silica 
or C-18 were used to purify the samples. Purification of samples removes the matrices and other 
unwanted impurities resulting in ideal samples for bioanalysis by chromatography and mass 
spectrometry. Precipitation methods using centrifuges, precipitation using solvents were also 
employed to purify the samples. Depending on the nature of the drugs and metabolites one or 
more of the above process has to be practiced for samples with high purity [40]. Highly pure 
samples result in reproducible quantification results. Along with purification of samples, choos-
ing an appropriate internal standard is also essential for quantification of drugs and metabo-
lites. The chosen internal standard should have structure similar to that of parent drug and 
should not interfere with parent drug during analysis. For ex internal standards should have 
different retention time and molecular weight compared to the drugs and metabolites. Thus 
chosen internal standards can be distinguished from parent drugs by LC–MS/MS during the 
analysis. Different retention time in chromatography and different multiple reaction monitor-
ing (MRM) transitions in mass spectrometry for internal standards with respect to that of parent 
drugs is essential for accurate quantitation of drugs and metabolites. Thus the separation power 
of chromatography and sensitivity of mass spectrometers are an added advantage for a phar-
macokineticist and toxicokineticist to determine the fate of new chemical entities (NCE’s) [41].
11. Identification of metabolites
Biotransformation of pharmaceutical drugs results in metabolites. Structural identification of 
metabolites by liquid chromatography and mass spectrometry confirm the metabolic softspots 
and hotspots [42, 9]. Metabolic softspots involve usual biotransformation pathways such as oxi-
dation, reduction, hydrogenation, dehydrogenation, hydroxylation, dehydroxylation, loss of a 
functional group, oxidative dehalogenation, epoxidation, decarboxylation,  hydration etc. [4]. 
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These are the major phase-I biotransformation along with few other unusual metabolic path-
ways. Apart from phase-I metabolites, conjugation reactions leads to phase-II metabolites 
such as glucuronidation, sulfation, glutathione formation, methylation, glycine conjugation, 
and taurine conjugation [4]. Identification of the structure of phase-I and phase-II metabolites 
and its quantity is essential to understand the elimination of drugs, metabolites and resi-
dence time of drugs, metabolites in human system. LC–MS/MS plays a crucial role in rapid 
identification of the metabolic soft spots and hot spots and directs synthetic chemists to make 
appropriate modifications in the drug moiety [43, 44].
12. Conclusions
In vitro biotransformation of pharmaceutical drugs utilizing matrices viz. microsomes, hepa-
tocytes, liver slices or liver S9 fractions results in various metabolites. Each matrix has its 
advantages and shortcomings. Therefore, all the matrices are essential to identify, confirm 
and quantify the metabolites. During the preclinical pharmaceutical candidate optimization, 
screening the pharmaceutical drugs using various matrices helps bioanalytical and biotrans-
formation scientists to identify the metabolic spots of the molecules with the aid of chro-
matography and mass spectrometry. Identification of metabolic spots at the early stage is 
beneficial for medicinal chemists to design and alter the structure of pharmaceutical drug for 
better potency and accelerate the drug discovery and development process.
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